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Background: Cyclophosphamide (Cy) is used in combination
with novel drugs for the treatment of newly diagnosed and
relapsedmultiplemyeloma (MM). In this retrospective study,
we report the University of Florida experience with Cy
maintenance therapy in patients who could not tolerate or
previously failed 1st line maintenance therapy after autolo-
gous stem cell transplantation (ASCT).
Methods: We evaluated MM patients who received in-
duction chemotherapy and ASCT from 2000 to 2010. The
patients were divided into four groups based on the main-
tenance therapy prescribed post ASCT or after ﬁrst relapse:
No maintenance (observation), interferon and/or prednisone
(I/P), immunomodulatory drugs (IMiDs; thalidomide or
lenalidomide), and Cy. Overall 32 patients received Cy for
maintenance. Cy was given as 200 mg/day orally x 10 days
every 28 days (n¼28) or IV 750 mg/m2 every 21 days (n¼4).
Progression free survival (PFS) and overall survival (OS) was
analyzed using the log-rank test. Group characteristics were
studied using descriptive statistics.
Results: 286 patients underwent ASCT; patients with less
than six months of post-ASCT follow-up (8) and those
treated with allogeneic transplant (21) were excluded. Of the
remaining 257 patients, 36 patients received tandem ASCT.
The cohort was 45.9% female with a mean age at diagnosis of
57.4 years. Eleven patients had Cy maintenance post ASCT
(Cy1) and 21 received Cy after 1st relapse and salvage
chemotherapy (Cy2). Median PFS (from ASCT) and OS (from
diagnosis) for the entire Cy group was 22.6 and 76 months,respectively. After ASCT, patients in the Cy1 group had
similar disease stage distribution but a lower rate of VGPR/CR
(18.2%) in comparison to the other groups. There was no
signiﬁcant difference in PFS or OS in the Cy1 group vs. the
IMiDs (n¼75) or the observation (n¼ 105) groups. Patients
treated with IMiDs maintenance had signiﬁcantly longer PFS
(P¼0.001) and OS (P¼0.0322) vs. observation. Cy was well
tolerated with a dose reduction necessary in one patient due
to cytopenias. A similar analysis for Cy2 showed no signiﬁ-
cant difference in PFS and OS between Cy and other main-
tenance therapies. Speciﬁcally, there was no signiﬁcant
difference in PFS (10.4 vs.17.6months, p¼0.07) and OS (mean
91.7 vs. 95.7 months, p¼0.08) of patients receiving Cy2 when
compared to the IMiDs group (n¼31). IMiDs maintenance
therapy again demonstrated superior OS in comparison to
observation (p ¼ 0.018) in the second-line setting. Cy2 was
well tolerated with dose reductions necessary in 3/21 pa-
tients (cytopenias [2] and nausea [1]); Cy was discontinued
in 4/21 due to cytopenias. One patient in Cy1 group devel-
oped hypoplastic myelodysplastic syndrome after > 3 years
on Cy.
Conclusions: Cy maintenance therapy may be an effective
and well-tolerated alternative after ASCT, particularly in the
second-line setting, and when other maintenance options
are not feasible.
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Background: Lymphoma represents the third most common
cancer under 15yrs of age and the most common cancer in
adolescents and young adults.(Hochberg/Cairo, BJH 2009)
Hodgkin Lymphoma occurs in approximately 7,500 people
per yr in the U.S. EBV infection has been suggested to be one
of several causative possibilities in its pathogenesis with
about 40% of HL being EBV-associated. Autologous T cells
directed to LMP1/2 antigens can induce durable responses in
high risk patients without signiﬁcant toxicity.(Bollard, JCO
2014) Although there have been signiﬁcantly improved
outcomes, those with progressive or relapsed disease often
require alternative strategies with limited good options.
Objectives: We intend to analyze the toxicity and overall
response rate of allogeneic HLA matched donor derived
latent membrane protein (LMP) speciﬁc-cytotoxic T cell
lymphocytes (CTLs) in children, adolescents and young
adults (CAYA) with EBV-associated refractory or relapsed
Hodgkin lymphoma (HL) following reduced intensity
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plantation (AlloSCT) from EBV positive HLA matched sibling
or unrelated adult donors.
Methods: EBV positive patients with poor-risk HL will
receive a reduced intensity conditioning regimen followed
by an allogeneic stem cell transplant from EBV positive HLA
matched sibling or unrelated adult donor combined with up
to three doses of post AlloSCT allogeneic donor derived LMP
speciﬁc cytotoxic T-lymphocyte (CTL) infusions (Fig 1A) as
previously described.(Bollard et al, Blood 2007)
Results: To date, our ﬁrst patient has successfully completed
therapy e a 20yr-old male with EBV+ relapsed/refractory
Hodgkin Lymphoma who received his donor EBV-CTL infu-
sion approximately 60 days post AlloSCT from an EBV+ 10/10
MUD donor without adverse effect or complication.
Conclusions: The development of this multicenter LCTC
consists of 9 outstanding multidisciplinary academic centers
(Fig 1B) that comprise expertise in CAYA clinical and trans-
lational lymphoma research, lymphoma biology and bio-
pathology, stem and cell therapy, targeted cell therapy
manufacturing (GMP), biostatistics and bioinformatics, and
expertise in state and federal regulatory compliance. This
consortium is poised to rapidly translate targeted cell ther-
apy in CAYA with high- or poor-risk lymphomas. Further
results from this trial will provide critical information to
develop future randomized trials investigating the use of
donor derived LMP-CTLs.
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Introduction: Allogeneic hematopoietic stem cell trans-
plantation (HSCT) is a potential curative treatment forPatients Donor CMV ab,
patient
CMV ab,
donor
MUD MRD Pos Neg Pos Neg
Female n[10 5 5 3 7 5 5
Male n[12 7 5 5 7 6 6relapsed Hodgkin’s Disease. Here we report the results from
a single center institution.
Materials and Methods: A retrospective study was per-
formed with 22 patients with Hodgkin’s Disease who un-
derwent non-myeloablative allogeneic (NMA) HSCT in the
period October 1996 to June 2014 at The Bone Marrow
Transplant Unit, Rigshospitalet, Copenhagen. All patients had
previously received multiple regimens of chemotherapy,
including HDT with autologous stem cell support, 7 patients
had CR at the time of transplantation, others had stable
disease/PR, Ann Arbor stage I-IV. The NMA conditioning
regimens were: Fludarabine 90 mg/m2 and TBI 2 Gy for 19
patients and the 3 patients who received umbilical cord
blood (UCB): Fludarabine 160 mg/m2, Cyclofosfamide
50 mg/kg and TBI 2 Gy. There were 12 males and 10 females,
median age 34.6 years, range 17 to 64.
Results: The overall survival rate was 29.7%, with a median
observation time of 30 months, range 1 to 154 months.
Fourteen of 22 patients developed acute graft versus host
disease grade 1 to 3. Thirteen of 22 died; causes of death
were: toxicity (n¼ 5), relapse/progressive disease (n¼ 6) and
other malignancies (n¼ 2).
Discussion: Despite a theoretical graft versus lymphoma
effect has been discussed in Hodgkin’s Disease, this effect
seems modest in our cohort. More efﬁcient allogeneic
transplant protocols are warranted for relapsed Hodgkin’s
disease.258
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Novel agents and autologous stem cell transplantation
(ASCT) have dramatically prolonged overall survival (OS) of
patients with multiple myeloma (MM). However, almost all
patients relapse within several years after ASCT and some
patients are refractory to standard treatment strategy. Allo-
geneic stem cell transplantation (allo-SCT) is potentially
curative treatment option because of its tumor free graft and
